Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
Stocks in this Quantisnow insightHealth Care
Historical context for UPB
Across the 11 sessions after earlier UPB headlines, the stock closed higher 5 times and lower 6 times, with a median move of 3.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | UPB | SPY |
|---|---|---|---|
| Mar 27, 2026 | Upstream Bio downgraded by Evercore ISI with a new price target | -11.4% | -1.7% |
| Mar 26, 2026 | Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results | +3.4% | -1.8% |
| Mar 2, 2026 | Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting | +0.3% | +0.1% |
| Feb 25, 2026 | Upstream Bio to Participate in Upcoming March Investor Conferences | -2.3% | +0.8% |
| Feb 11, 2026 | Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthmaand 1 other headline that session | -47.2% | -0.0% |
| Jan 5, 2026 | Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference | -3.5% | +0.7% |
Keep researching UPB
Quantisnow market dataNASDAQ
UPB
Upstream Bio Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2024
Get push alerts for UPB
Full UPB profile on Quantisnow Follow UPB and get a push notification the moment its next story breaks.